NCT06878625View on ClinicalTrials.gov

A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
Interventions
COMBINATION_PRODUCT

Sacituzumab Govitecan combined with Toripalimab

Sacituzumab Govitecan combined with Toripalimab

COMBINATION_PRODUCT

Sacituzumab govitecan combined with anti-angiogenesis

Sacituzumab govitecan combined with anti-angiogenesis( Bevacizumab or Anlotinib Hydrochloride)

Trial Locations (1)

300000

RECRUITING

Tianjin Cancer Hospital Airport Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER